 |
|
|
| |
Predictors of Virologic Response with Telaprevir-based Combination Treatment in HCV Genotype 1-infected Patients with Prior Peginterferon/ribavirin Treatment Failure: Post-hoc Analysis of the Phase III REALIZE Study
|
| |
| |
Reported by Jules Levin
AASLD Nov 5-9 2011
T Berg,1 P Andreone,2 S Pol,3 S Roberts,4 Z Younossi,5 M Diago,6 EJ Lawitz,7 R Focaccia,8 GR Foster,9 A Horban,10 I Lonjon-Domanec,11 R DeMasi,12 G Picchio,12
J Witek,12 S Zeuzem13
1Universitätsklinikum Leipzig, Sektion Hepatologie, Klinik fur Gastroenterologie und Rheumatologie, Leipzig, Germany;
2Universita di Bologna, Bologna, Italy; 3Université Paris Descartes, INSERM Unité 1016, and Assistance Publique-Hopitaux
de Paris, Cochin Hospital, Paris, France; 4Department of Gastroenterology, Alfred Hospital, Melbourne, VIC, Australia;
5Center for Liver Diseases and Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, USA; 6Hospital General de Valencia, Valencia, Spain; 7Alamo Medical Research, San Antonio, TX, USA; 8Emilio Ribas Infectious Diseases Institute, Sao Paulo, Brazil; 9Queen Marys University of London, Institute of Cell and Molecular Science, London, UK; 10Medical University of Warsaw, Wolska, Warsaw, Poland; 11Janssen Pharmaceuticals, Paris, France; 12Tibotec Inc., Titusville, NJ, USA, 13Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany
|
| |
|
|
|
|
|
